NCT07279558 Cannabidiol and Alcohol Use Disorder Phenotypes
| NCT ID | NCT07279558 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of Colorado, Denver |
| Condition | Alcohol Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2026-03-31 |
| Primary Completion | 2029-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 150 participants in total. It began in 2026-03-31 with a primary completion date of 2029-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to learn how CBD affects drinking in people who drink alcohol regularly. Researchers want to see if CBD can help people drink less and reduce problems related to alcohol use.
Eligibility Criteria
Inclusion Criteria: 1. Age 21-65 2. Have used CBD and cannabis at least once in the last year 3. Regularly drink alcohol 4. Able to provide informed consent and attend in-person study visits Exclusion Criteria: 1. Current use of medications known to have major interaction with Epidiolex, Marinol, or alcohol 2. Current use of antiepileptic medication or any psychotropic medication besides antidepressants 3. Pregnant, nursing, or planning a pregnancy 4. Medical conditions that contraindicates the use of CBD or alcohol 5. Current medical conditions that may require intensive care during the study period Not everyone will qualify to be in the study. Other inclusion and exclusion criteria will be evaluated by the study team.
Contact & Investigator
Hollis C Karoly, PhD
PRINCIPAL INVESTIGATOR
University of Colorado School of Medicine- Anschutz Medical Campus
Frequently Asked Questions
Who can join the NCT07279558 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 65 Years, studying Alcohol Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07279558 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07279558 currently recruiting?
Yes, NCT07279558 is actively recruiting participants. Contact the research team at hollis.karoly@cuanschutz.edu for enrollment information.
Where is the NCT07279558 trial being conducted?
This trial is being conducted at Aurora, United States.
Who is sponsoring the NCT07279558 clinical trial?
NCT07279558 is sponsored by University of Colorado, Denver. The principal investigator is Hollis C Karoly, PhD at University of Colorado School of Medicine- Anschutz Medical Campus. The trial plans to enroll 150 participants.